Cargando…
Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics
Rationale: Fibroblast activation protein (FAP) targeted molecular imaging radiotracers have shown promising preclinical and clinical results in tumor diagnosis. However, rapid clearance and inadequate tumor retention of these molecules have hindered them for further clinical translation in cancer th...
Autores principales: | Wen, Xuejun, Xu, Pengfei, Shi, Mengqi, Liu, Jia, Zeng, Xinying, Zhang, Yiren, Shi, Changrong, Li, Jingchao, Guo, Zhide, Zhang, Xianzhong, Khong, Pek-Lan, Chen, Xiaoyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690933/ https://www.ncbi.nlm.nih.gov/pubmed/34987657 http://dx.doi.org/10.7150/thno.68182 |
Ejemplares similares
-
Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding
por: Chen, Haojun, et al.
Publicado: (2016) -
Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [(68)Ga]Ga-FAPI-RGD
por: Zang, Jie, et al.
Publicado: (2022) -
Pd nanosheets with their surface coordinated by radioactive iodide as a high-performance theranostic nanoagent for orthotopic hepatocellular carcinoma imaging and cancer therapy
por: Chen, Mei, et al.
Publicado: (2018) -
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
por: Shi, Mengqi, et al.
Publicado: (2022) -
“Albumin Hitchhiking” with an Evans Blue Analog for Cancer Theranostics
por: Ehlerding, Emily B., et al.
Publicado: (2018)